Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.44% is 77% below its 2-year average of 6.24%, near the low end of its 2-year range (0.00%–19.54%).
As of the fiscal period ended Tuesday, June 30, 2026. 70.13% below its 12-month average of 4.83%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.44%.
DEBT TO ASSETS RATIO
1.44%
DEBT TO ASSETS RATIO AVG TTM
4.83%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-70.13%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1502.65%
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$984.47M
Debt to Assets Ratio
1.44%
TTM Avg
4.83%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$986.75M
Debt to Assets Ratio
0.28%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.72M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$994.10M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.96M
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$959.28M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $984.47M | 1.44% | 4.83% | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $986.75M | 0.28% | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $987.72M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $994.10M | 0.16% | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.96M | 0.33% | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $998.37M | 0.01% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.01% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.03% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $959.28M | 0.02% | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $957.83M | 0.16% | N/A | N/A | N/A |
Debt/Assets
1.4%
Debt/Equity
0.02
Current Ratio
15.08
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.44% |
| 2026-03-31 | 0.88% |
| 2025-12-31 | 1.14% |
| 2025-09-30 | 1.14% |
| 2025-06-30 | 19.54% |
| 2025-03-31 | 19.54% |
| 2024-03-31 | 0.00% |
